Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;44(5):611-613.
doi: 10.1007/s40264-021-01059-x. Epub 2021 Apr 9.

Authors' Reply to Michael Auerbach's Comment on: "Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System"

Henry Trumbo  1 , Karolina Kaluza  2 , Syed Numan  2 , Lawrence T Goodnough  3
Affiliations
Comment

Authors' Reply to Michael Auerbach's Comment on: "Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System"

Henry Trumbo et al. Drug Saf. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Henry Trumbo is a consultant for American Regent, Daiichi Sankyo, and Allergan. Lawrence T. Goodnough is a consultant for American Regent. Karolina Kaluza and Syed Numan are employees of American Regent, the manufacturers of ferric carboxymaltose.

Comment on

Similar articles

See all similar articles

References

    1. Trumbo H, Kaluza K, Numan S, Goodnough LT. Frequency and associated costs of anaphylaxis- and hypersensitivity-related adverse events for intravenous iron products in the USA: an analysis using the US Food and Drug Administration Adverse Event Reporting System. Drug Saf. 2020 doi: 10.1007/s40264-020-01022-2. - DOI - PMC - PubMed
    1. Auerbach M. Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”. Drug Saf. 2021. 10.1007/s40264-021-01058-y. - PubMed
    1. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650–654. doi: 10.1002/ajh.21794. - DOI - PubMed
    1. Downing NS, Shah ND, Aminawung JA, et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration Between 2001 and 2010. JAMA. 2017;317(18):1854–1863. doi: 10.1001/jama.2017.5150. - DOI - PMC - PubMed
    1. Potts J, Genov G, Segec A, et al. Improving the safety of medicines in the European Union: from signals to action. Clin Pharmacol Ther. 2020;107(3):521–529. doi: 10.1002/cpt.1678. - DOI - PMC - PubMed

LinkOut - more resources